Promescent Review: Pricing, Products, and What to Expect

Premature ejaculation has a direct physiological mechanism: excessive sensitivity of the glans penis leads to rapid stimulation of the ejaculatory reflex. Reducing that sensitivity - without reducing it so much that erection or pleasurable sensation is eliminated - is the pharmacological target. Promescent uses benzocaine (7.5% concentration) as its active ingredient. Benzocaine is a local anesthetic that temporarily blocks sodium channels in sensory nerve endings, reducing sensitivity. The key engineering challenge is application: apply too much to the wrong area at the wrong time, and you transfer the anesthetic to your partner, numbing them as well. Apply too little, and there is no useful effect. Promescent's TargetZone Absorption Technology is designed to address this transfer problem. The spray formulation uses a carrier that promotes rapid absorption into the penile tissue rather than sitting on the surface as a cream or gel would. The faster absorption window means that by the time sexual activity begins, the benzocaine is in the tissue where it produces the desensitizing effect rather than on the surface where it can transfer. The spray is applied 10-15 minutes before intercourse, which allows time for absorption. Clinical guidance recommends starting with 3 sprays (the minimum effective dose) and adjusting based on experience - down if excessive numbness occurs, up (maximum 10 sprays) if the effect is insufficient. The effect lasts approximately 60-90 minutes, declining gradually as the anesthetic metabolizes. The claimed advantage over older desensitizing products (sprays and creams that used to be the standard) is less partner transfer and better maintenance of pleasurable sensation for the user. If you are fully numb, sex becomes mechanical and potentially impossible to maintain erection. The goal is calibrated reduction, not complete desensitization.

Most over-the-counter sexual wellness products have no published clinical data. Promescent is an exception. The company funded a randomized, double-blind, placebo-controlled crossover study published in Therapeutic Advances in Urology (2014) that evaluated the spray in 54 men with PE. The primary outcome was intravaginal ejaculatory latency time (IELT) - the time from vaginal penetration to ejaculation. In the Promescent group, IELT increased by 64% compared to baseline (from mean 1.07 minutes to 1.76 minutes) versus an 11% increase in the placebo group. The difference was statistically significant. Secondary outcomes included self-reported satisfaction for both the men and their partners, which also improved considerably in the Promescent group versus placebo. To contextualize what these numbers mean clinically: a baseline IELT of 1.07 minutes represents medically defined PE (ejaculation within approximately 1-2 minutes of penetration, causing distress). The improvement to 1.76 minutes is clinically meaningful and statistically significant, though it remains below the approximately 3-5 minute average IELT in men without PE. For men who previously ejaculated immediately or within seconds, the improvement is functionally more significant than the absolute numbers suggest. The study also measured partner transfer of benzocaine - finding no measurable transfer when application instructions were followed, supporting the TargetZone absorption claim.

The standard behavioral approaches to PE - the start-stop technique and squeeze technique - have evidence supporting their effectiveness, with studies showing ejaculatory latency improvements comparable to pharmacological treatment in motivated patients with mild PE. Promescent positions its spray as a complement to these techniques, not a replacement.

For men who have already tried behavioral techniques without sufficient success, or who find behavioral techniques disruptive to spontaneous sexual experiences, the spray provides an alternative pathway. For men starting PE treatment for the first time, combining both approaches typically produces better outcomes than either alone.

The prescription pharmacological option for PE is dapoxetine - an SSRI specifically designed with a short half-life for on-demand dosing. It is approved in many countries but has not received FDA approval in the United States and is not currently commercially available in the US market. Off-label use of other SSRIs (paroxetine, sertraline, fluoxetine) on a daily basis is a standard clinical practice for PE in the US, with delayed ejaculation as a known side effect that is therapeutic in this context.

Promescent sits between the purely behavioral and the prescription pharmacological approaches. It does not require a prescription, has no systemic side effects, works on-demand without daily medication, and has published clinical evidence. For men who want an intervention for PE without the commitment to daily SSRIs, the spray is a reasonable choice.

While the desensitizing spray is the flagship, Promescent has expanded into a broader sexual wellness portfolio:

Desensitizing spray: The original product. FDA-compliant OTC formula. 7.5% benzocaine. $19.95 for 7.5ml (approximately 30-35 applications at starting dose of 3 sprays).

VitaFLUX supplements (male): A supplement stack targeting vascular health, testosterone support, and sperm quality. Includes L-arginine, L-citrulline (NO precursors for vascular function), zinc, vitamin D3, coenzyme Q10. $49.95/month. No prescription required.

Warming female arousal gel: A topical arousal enhancement gel for women. OTC, non-prescription. Ingredients include L-arginine and niacin for increased blood flow. $29.95.

Male arousal gel: Topical gel formulated to improve penile sensitivity in a positive direction (as opposed to the desensitizing spray). For men who experience reduced sensitivity from medications or age. OTC. $29.95.

Delay wipes: Single-use wipes with the same desensitizing formula as the spray, individually packaged for convenience and discretion. $24.95 for 10 wipes.

Condom-compatible lubricant: Silicone-free water-based lubricant. $19.95.

The product line has expanded beyond its PE roots into general sexual wellness, which broadens the appeal but also moves into categories where the clinical differentiation is less pronounced. The supplements are reasonable formulations but do not have the same peer-reviewed clinical backing as the spray.

Promescent has added prescription ED medications to its portfolio through a telehealth platform, though this is not the company core identity. Through the Promescent telehealth service, providers can prescribe sildenafil, tadalafil, and other ED medications. The intake process follows the standard async telehealth model - form, provider review, prescription if appropriate.

For ED prescriptions specifically, Promescent is a functional but not specialized option. Dedicated ED telehealth platforms (hims, Ro, Roman) have more developed ED programs, more prescribing options (including branded medications, injections, topical formulas), and a longer track record in this specific category.

What Promescent uniquely offers for combined PE and ED: a single platform where men dealing with both conditions - which frequently co-occur, as anxiety about one condition often triggers or worsens the other - can access products for both. The desensitizing spray for PE and a tadalafil prescription for ED managed through the same portal is a practical convenience.

The psychological interaction between PE and ED is clinically recognized. Men who develop anxiety about PE often experience performance anxiety that contributes to ED. Treating both simultaneously rather than sequentially can be clinically more effective. Promescent is positioned to address both conditions in a way that most platforms, which focus on one or the other, are not.

Promescent has invested meaningfully in addressing the relational dimension of PE treatment, which most products in the category ignore entirely. The company produces educational content about how PE affects both partners, how to communicate about it, and how to approach treatment as a couple rather than as an individual dysfunction.

This framing matters clinically. Research consistently shows that partner involvement in PE treatment improves outcomes - both in terms of ejaculatory control improvement and relationship satisfaction. Men who work on PE treatment with partner knowledge and support do better than men who try to manage it covertly.

For the spray specifically, partner experience has a practical dimension: the concern about transfer of the anesthetic to the partner is one of the most common objections. The published data on minimal transfer under correct application conditions, and the practical guidance Promescent provides on application timing and technique, address this directly.

The warming arousal gel for women, developed in part to improve the female partner experience during PE-oriented sex (which often involves extended non-intercourse activity to manage the male ejaculatory response), is a product line extension that reflects this couple-focused philosophy.

Promescent products are available direct-to-consumer on the Promescent website and on Amazon. The OTC products do not require a prescription, a telehealth consultation, or a waiting period. You order, it ships, it arrives.

Pricing:

• Desensitizing spray: $19.95 (7.5ml, ~30-35 applications at minimum dose) to $49.95 (45ml, ~150-170 applications)
• VitaFLUX supplements: $49.95/month
• Delay wipes: $24.95 for 10 wipes
• Female arousal gel: $29.95

On a per-use basis, the spray at the starting dose (3 sprays) costs approximately $0.50-1.00 per use on the larger format - far less than prescription alternatives.

Amazon availability means next-day delivery through Prime is an option, which removes the waiting period for new users. Discretion is maintained: Amazon packaging does not advertise the contents.

The telehealth service for ED prescriptions requires the standard intake consultation and shipping of prescription medication, following normal telehealth timelines (prescription review 1-24 hours, shipping 3-5 business days).

Most telehealth platforms that offer PE treatment prescribe off-label SSRIs (paroxetine, sertraline, clomipramine) on a daily or on-demand basis. Paroxetine produces the greatest ejaculatory delay in clinical trials, extending intravaginal ejaculatory latency time by a factor of 8-11x at therapeutic doses.

Promescent offers an on-demand, non-prescription, topically-applied alternative with fewer systemic effects and actual published clinical data. For men who prefer not to take daily medication for a situational concern, or who want to address PE in specific situations rather than changing their baseline physiology, the spray is a meaningful alternative.

The comparison to other topical products: older desensitizing products (Stud 100, various benzocaine creams) lack Promescent's absorption technology and published data on partner transfer. The clinical evidence and formulation engineering create a differentiated product within the benzocaine spray category.

The limitation is absolute efficacy ceiling. The spray approximately doubles IELT from the PE baseline - from just over 1 minute to about 1.75 minutes. For some men, this is sufficient to move from distressing early ejaculation to manageable experience. For men who want to reach more typical IELT times (3-5 minutes or more), behavioral training, daily SSRIs, or a combination approach typically produces larger improvements.

The spray is compact (7.5ml bottle, pocket-sized) and is not obviously a medical product in packaging or appearance. The label reads "Promescent Desensitizing Spray" without explicit health disclosure language on the exterior. For men who share a bathroom or living space, discretion is inherently easier than with prescription medication bottles or visible telehealth prescription packaging.

Application technique matters for both efficacy and partner experience. The Promescent website and packaging provide detailed instructions: apply 3 sprays (starting dose) to the glans and frenulum 10-15 minutes before intercourse. Allow to absorb - do not rub vigorously. Washing hands after application prevents transfer to other areas. Proceeding to sexual activity before the absorption window (10 minutes minimum) increases transfer risk.

First-time users frequently start with 3 sprays and adjust based on experience. Some men find 3 sprays insufficient for meaningful delay; 5-7 sprays is a common effective dose. Going over 10 sprays is not recommended and likely to produce excessive numbness that interferes with erection maintenance.

Using the spray consistently for 3-4 occasions allows calibration of the right dose and timing for your physiology before trying it in a partnered context - a practical recommendation the company makes and that most users find helpful.